Calamos Asset Management has a market cap of $224 million and an enterprise value of -$184 million. This stock trades at a reasonable valuation, with a trailing price-to-earnings of 12.53 and a forward price-to-earnings of 14.91. Its estimated growth rate for this year is -19.3%, and for next year it's pegged at 4.2%. This is a cash-rich company, since the total cash position on its balance sheet is $498.68 million and its total debt is just $92.11 million.

The CEO just bought 133,653 shares, or about $1.46 million worth of stock, at $10.82 to $11 per share. This same CEO also just bought 114,957 shares, or about $1.21 million worth of stock, at $10.47 to $10.76 per share.

From a technical perspective, CLMS is currently trending above both its 50-day and 200-day moving averages, which is bullish. This stock has been uptrending strong for the last month and change, with shares moving higher from its low of $9.48 to its intraday high of $11.09 a share. During that uptrend, shares of CLMS have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now started to push shares of CLMS into breakout territory above some past overhead resistance levels at $10.84 to $10.93 a share.

If you're in the bull camp on CLMS, then look for long-biased as long as it's trending above those breakout levels at $10.84 to $10.93 a share with strong upside volume flows. Look for a sustained move or close above those breakout levels with volume that registers near or above its three-month average action of 183,289 shares. If CLMS can maintain that trend, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $11.82 to $12.50 a share.

General Motors

One stock that insiders are jumping into here is General Motors ( GM), which develops, produces and markets cars, trucks and parts worldwide. Insiders are buying this stock into some notable strength, since shares are up 28% during the last six months.

General Motors has a market cap of $37 billion and an enterprise value of $25 billion. This stock trades at a cheap valuation, with a trailing price-to-earnings of 9.32 and a forward price-to-earnings of 6.24. Its estimated growth rate for this year is 5.2%, and for next year it's pegged at 27.9%. This is a cash-rich company, since the total cash position on its balance sheet is $26.12 billion and its total debt is $16.05 billion.

If you liked this article you might like

Closing the Door on Abiomed

Capturing Profits on AIG

A Roundup of My Open Positions

Pumped Up About Abiomed Collar Play

Masimo's Stock Is a Great Buy Right Now